Aldeyra Therapeutics, Inc. (ALDX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Aldeyra Therapeutics, Inc. (ALDX) closed at USD 0.79 on 2026-10-14, a change of -84.6 % over the past year, with a market capitalization of USD 44.48M.

Aldeyra Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Aldeyra Therapeutics, Inc. key figures

Previous close

USD 0.79 (2026-10-14)

1-year change

-84.6 %

Market cap

USD 44.48M

Enterprise value

USD -467,668

P/E ratio (trailing)

-2.38

P/E ratio (forward)

-2.68

EPS (trailing)

-0.31

EPS (forward)

-0.28

PEG ratio

n/a

Price to book

1.17

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.70

Employees

6

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Aldeyra Therapeutics, Inc. and compare it with other stocks.